UCI 趙 Chao Family Comprehensive Cancer Center



Head and Neck Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison
Anastasiia Reipolska

Open to Accrual | Low Accruing | Pending Activation/Suspended

Head & Neck

Neoadjuvant HNSCC

ETCTN 10706
Cemiplimab vs CDX-1140 + Sx
Locally Advanced Resectable HNSCC
PI: Dr. Villaflor
Coord: A. Reipolska
Accrual: 2/5

ETCTN 10721
Carbo/Taxol +/- Cemiplimab, Sx
Locally Advanced SNSCC
PI: Dr. Kuan
Coord: N. Arechiga
Accrual: 0/5

HN015
Sx alone vs Carbo/taxel + Sx vs Carbo/Taxel + Cemiplimab + Sx
Locally Advanced HNSCC/Recurrent
PI: Dr. Villaflor
Coord: Bao H.
Accrual: 0/12

UCI 25-230
Sx +/- APG-157 (PO),
Induciton CRT+/- APG-157 + Sx
Locally Advanced HNSCC
PI: Dr. Haidar
Coord: TBD
Accrual: 0/10
PSSV 7/14/26

Definitive HNSCC

UCI 22-132
De-escalated Radiation HPV 16+ SCC OPC
PI: Dr. Chen
Coord: E. Palmer-Torrison
Accrual: 26/111

UCI 21-173
AHCC w/ SOC Tx
HPV+ HNSCC
PI: Dr. Nabar
Coord: A. Reipolska
Mushroom Extract
Accrual: 11/25

Re-radiation

EA3191
Pembrolizumab
Adjuvant Recurrent/2ndary HNSCC
Attarian
Coord: N. Arechiga
Accrual: 0/5

Adjuvant

EA3132 (TP53)
XRT +/- Cisplatin
Adjuvant
Dr. Attarian
Coord: A. Reipolska
Accrual: 0/5

Open to Accrual | Low Accruing | Pending Activation/Suspended

Head and Neck

1st Line Recurrent/Metastatic HNSCC

RTOG 3521
Gem+Cis+ Tori
1st line Recurrent/Metastatic NPC
PI: Attarian
Coord: N. Arechiga
Accrual: 1/5

UCI 26-145
Abbvie
Telisotuzumab Adizutecan + Pembrolizumab
Recurrent or 1st line Metastatic HNSCC
PI: Dr. Villaflor
Coord: Natalie A.

Recurrent/Metastatic

UCI 25-49
Petosemtamab vs Phys Choice
Recurrent HNSCC
PI: Attarian
CRC: E. Palmer-Torrison
Accrual: 1/5

Alliance A092105
2nd line Ipi/Nivo +/- Cabozantinib
Recurrent NPC
PI: Attarian
Coord: B. Huynh
Accrual: 2/5

S2101
Nivo + Cabozantinib
HNSCC, Melanoma
PI: Dr. Vaidya
Coord: Natalie A
Accrual: 7/12

EA3231
BRAF Agent vs Cabozantinib
Recurrent Thyroid Cancer
PI: Attarian
Coord: E. Palmer-Torrison
Accrual: 0/5

SWOG-21CTP-HN01
Amivantimab, Carboplatin, Paclitaxel
Recurrent HNSCC
PI: Nabar
CRC: E. Palmer-Torrison
Accrual: 1/5

Open to Accrual | Low Accruing | Pending Activation/Suspended

Broad Phase 1 Trials

UCI 25-106
BMS ADC TOPO1 inhibitor
HNSCC, 2L+ sq/nsq NSCLC, TNBC
PI: Dr. Nabar
Coord: N. Arechiga
Accrual: 2/5

UCI 25-170
Immunogenesis
HNSCC, 2L+ sq/nsq NSCLC, TNBC
Dr. Villaflor
Coord: Erin Palmer-Torrison
Accrual: 2/5

UCI 22-09
B7-H4–targeted antibody-drug conjugate
ACC-I
PI: Dr. Parajuli
CRC: N. Arechiga
Accrual: 7/10
Waitlist only

UCI 24-113
Ikaros zinc finger
HNSCC, Melanoma, NSCLC, TNBC
PI: Dr. Chow
Coord: Natalie A.
Accrual: 5/10

UCI 24-142 (KaliVir)
Squamous cell basket, including SCCHN and SCCL, Dermatologic malignancies (e.g., Merkel cell carcinoma, cutaneous squamous cell carcinoma), RCC, Urothelial carcinoma (other GU malignancies such as PCA following a discussion with us) Cervical cancer, MSS-CRC
VET3-TGI (sq/intratumoral) +/- Atezolizumab
PI: Uchio
Coord: TBD
Accrual: 2/4
Waitlist only

Head & Neck

Open to Accrual | Low Accruing | Pending Activation/Suspended

Supportive Care

Brain Fog

UCI 24-05
Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*
BREAST COHORT FULL
PI: Chan
CRC: A. Reipolska
Accrual: 26/39

UCI 24-87 (Arter IIT):
Mechanism: Methionine Reduced Diet
CRC: B. Huynh
PI: Dr. Arter
Accrual: 5/25

UCI 25-48
Riluzole PO vs. Placebo PO
Preventative worsening of cognitive function
PI: Chan
CRC: A. Reipolska
Accrual: 6/20